MapLight Therapeutics
Clinical trials sponsored by MapLight Therapeutics, explained in plain language.
-
New drug ML-004 moves to safety testing in autism patients
Disease control OngoingThis study is testing the safety of an experimental drug called ML-004 in 120 adolescents and adults with autism spectrum disorder who have already completed a previous study. Participants will take ML-004 once daily, and researchers will monitor for side effects. The goal is to …
Phase 2 • Sponsor: MapLight Therapeutics • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New hope for Alzheimer's psychosis: Long-Term drug trial underway
Symptom relief By invitation onlyThis study is testing the long-term safety of a drug called ML007C-MA for people with Alzheimer's disease who also have hallucinations and delusions. About 210 adults who completed a previous study will take the drug twice daily for up to 52 weeks. The goal is to see if the drug …
Phase 2 • Sponsor: MapLight Therapeutics • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC